An Clinical Study of Evecare Forte Liquid in PCOS (Polycystic Ovarian Syndrome)

An Open Label Clinical Study to Evaluate the Efficacy and Safety of Evecare Forte Liquid in PCOS (Polycystic Ovarian Syndrome)â??

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/12/011004

Enrollment

Registered

2017-12-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Evecare Forte Liquid: 20 ml twice daily for 3 months Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Women with signs and symptoms of PCOS like irregular menstrual cycles, weight gain, biochemical/clinical hyperandrogenemia, hirsutism etc. 2. History of PCOS with 3. PCOS confirmed by Clinical and/or biochemical and/or ultrasonographical findings. 4. Willingness to sign consent for study including participation with collection of blood specimens.

Exclusion criteria

Exclusion criteria: 1. Patients who is not using oral contraceptive pills, hormonal treatment or IUCDs. 2. Patients who had no systemic illness like hypertension, renal disease, tuberculosis, hepatic disease, diabetes, coagulation disorder, etc. 3. Patients with organic lesion of the reproductive tract especially any benign or malignant growth, extensive cervical erosion, cervical polyps, endometriosis. 4. Patients with severe Hepatic/ cardiac/ mental illness. 5. Patients unwilling to provide informed consent or abide by the requirements of the study.

Design outcomes

Primary

Measure	Time frame
Efficacy of Evecare Forte Liquid, To regulate the frequency and variability of menstrual cycle,Improvement in hormonal and metabolic profile,To normalise changes in ovary on ultrasonography.Timepoint: Visit 0- At entry visit, baseline Visit 1- At the end of 1st month Visit 2- At the end of 2nd month Visit 3 (End of the study) - At the end of 3 months.	—

Secondary

Measure	Time frame
safety profile of Evecare Forte Liquid in PCOS, incidence of adverse events during the study period, and overall compliance to the drug treatment.Timepoint: Visit 0- At entry visit, baseline Visit 1- At the end of 1st month Visit 2- At the end of 2nd month Visit 3 (End of the study) - At the end of 3 months.	—

Countries

India

Contacts

Public ContactDr Y K Sharma

Board of Ayurvedic and Unani Systems of Medicine

dryks2@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026